A review of pharmacological treatments used in experimental models of traumatic brain injury

References

• Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta (GA) 2004
   Google Scholar
• Thurman DJ. The epidemiology and economics of head trauma. Head trauma: basic, preclinical, and clinical directions, L Miller, R Hayes. Wiley and Sons, New York 2001
   Google Scholar
• Jorge RE, Starkstein SE. Pathophysiologic aspects of major depression following traumatic brain injury. Journal of Head Trauma Rehabilitation 2005; 20: 475–487
   PubMed Web of Science ®Google Scholar
• Thurman DJ, Alverson CA, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: A public health perspective. Journal of Head Trauma Rehabilitation 1999; 14: 602–15
   PubMed Web of Science ®Google Scholar
• Parton A, Coulthard E, Husain M. Neuropharmacological modulation of cognitive deficits after brain damage. Current Opinion in Neurology 2005; 18: 675–680
   PubMed Web of Science ®Google Scholar
• Salmond CH, Sahakian BJ. Cognitive outcome in traumatic brain injury survivors. Current Opinion in Critical Care 2005; 11: 111–116
   PubMed Web of Science ®Google Scholar
• Capruso DX, Levin HS. Cognitive impairment following closed head injury. Neurology Clinics 1992; 10: 879–893
   PubMed Web of Science ®Google Scholar
• Levin HS, Goldstein FC, High Jr WM, Eisenberg HM. Disproportionately severe memory deficit in relation to normal intellectual functioning after closed head injury. Journal of Neurology, Neurosurgery & Psychiatry 1988; 51: 14–20
   PubMed Web of Science ®Google Scholar
• Phillips JP, Devier DJ, Feeney DM. Rehabilitation pharmacology: Bridging laboratory work to clinical application. Journal of Head Trauma Rehabilitation 2003; 18: 342–356
   PubMed Web of Science ®Google Scholar
• Whiting MD, Hamm RJ. Treating chronic cognitive impairment after traumatic brain injury: A review of post-traumatic neurotransmitter-based interventions. Critical Reviews in Physical & Rehabilitation Medicine 2004; 16: 273–290
   Google Scholar
• von Monakow C. Diaschisis, the localization in the cerebrum and functional impairment by cortical loci. Brand and behavior: Moods, states, and mind, K Pribram. Penguin Books, Baltimore 1969; 1, : 27–36, (translated by G. Harris)
   Google Scholar
• Feeney DM. Pharmacologic modulation of recovery after brain injury: A reconsideration of diachisis. Journal of Neurological Rehabilitation 1991; 5: 113–128
   Google Scholar
• Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989; 244: 798–800
   PubMed Web of Science ®Google Scholar
• Katayama Y, Becker DP, Tamura T, Hovda DA. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. Journal of Neurosurgery 1990; 73: 889–900
   PubMed Web of Science ®Google Scholar
• McIntosh TK. Novel pharmacologic therapies in the treatment of experimental traumatic brain injury: A review. Journal of Neurotruma 1993; 10: 215–261
   PubMed Web of Science ®Google Scholar
• Yoshino A, Hovda DA, Kawamata T, Katayama Y, Becker DP. Dynamic changes in local cerebral glucose utilization following cerebral concussion in rats: Evidence of hyper- and subsequent hypometabolic state. Brain Research 1991; 561: 106–119
   PubMed Web of Science ®Google Scholar
• Dixon CE, Bao J, Liu S, Johnson K, Hayes RL. Cortical impact produces chronic cholinergic deficits that are associated with reduced Ach release and can be attenuated behaviorally by CDP-choline. Journal of Neurotrama 1994; 11: 107
   Google Scholar
• Levin BE, Brown KL, Pawar G, Dunn-Meynell A. Widespread and lateralized effects of acute traumatic brain injury on norepinephrine turnover in the rat brain. Brain Research 1995; 674: 307–313
   PubMed Web of Science ®Google Scholar
• McIntosh TK, Yu T, Gennarelli TA. Alterations in regional brain catecholamine concentrations after experimental brain injury in the rat. Journal of Neurochemistry 1994; 63: 1426–1433
   PubMed Web of Science ®Google Scholar
• Prasad MR, Ramaiah C, McIntosh TK, Dempsey RJ, Hipkens S, Yurek D. Regional levels of lactate and norepinephrine after experimental brain injury. Journal of Neurochemistry 1994; 63: 1086–1094
   PubMed Web of Science ®Google Scholar
• Hamm RJ, O’Dell DM, Pike BR, Lyeth BG. Cognitive impairment following traumatic brain injury: The effect of pre- and post-injury administration of scopolamine and MK-801. Brain Research and Cognitive Brain Research 1993; 1: 223–226
   PubMedGoogle Scholar
• Pike BR, Hamm RJ, Temple MD, Buck DL, Lyeth BG. Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury. Journal of Neurotrauma 1997; 14: 897–905
   PubMed Web of Science ®Google Scholar
• Wilson MS, Hamm RJ. Effects of fluoxetine on the 5-HT1Areceptor and recovery of cognitive function after traumatic brain injury in rats. American Journal of Physical and Medical Rehabilitation 2002; 81: 364–372
   PubMed Web of Science ®Google Scholar
• Catatayud Maldonado V, Calatayud Perez JB, Aso Escario J. Effects of CDP-choline on the recovery of patients with head injury. Journal of Neurological Science 1991; 103: S15–18
   PubMed Web of Science ®Google Scholar
• Plenger PM, Dixon CE, Castillo RM, Frankowski RE, Yablon SA, Levin HS. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: A preliminary double-blind placebo-controlled study. Archives of Physical and Medical Rehabilitation 1996; 77: 536–540
   PubMed Web of Science ®Google Scholar
• Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: An initial double-blind placebo-controlled study. Brain Injury 1999; 13: 863–872
   PubMed Web of Science ®Google Scholar
• Lu D, Mahmood A, Chopp M. Biologic transplantation and neurotrophin-induced neuroplasticity after traumatic brain injury. Journal of Head Trauma Rehabilitation 2003; 18: 357–376
   PubMed Web of Science ®Google Scholar
• Glenn MB, Wroblewski B. Twenty years of pharmacology. Journal of Head Trauma Rehabilitation 2005; 20: 51–61
   PubMed Web of Science ®Google Scholar
• Napolitano E, Elovic EP, Qureshi AI. Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury. Medical Science Monitor 2005; 11: RA212–220
   PubMed Web of Science ®Google Scholar
• McAllister TW, Flashman LA, Sparling MB, Saykin AJ. Working memory deficits after traumatic brain injury: Catecholaminergic mechanisms and prospects for treatment – A review. Brain Injury 2004; 18: 331–350
   PubMed Web of Science ®Google Scholar
• Hamill RW, Woolf PD, McDonald JV, Lee LA, Kelly M. Catecholamines predict outcome after traumatic brain injury. Annals of Neurology 1987; 21: 438–443
   PubMed Web of Science ®Google Scholar
• Leone H, Polsonetti BW. Amantadine for traumatic brain injury: Does it improve cognition and reduce agitation?. Journal of Clinical Pharmacology Therapy 2005; 30: 101–104
   PubMed Web of Science ®Google Scholar
• Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Research 1994; 662: 255–258
   PubMed Web of Science ®Google Scholar
• Kraus M, Maki P. Case report: The combined use of amantadine and dopa/carbidopa in the treatment of chronic brain injury. Brain Injury 1997; 11: 455–460
   PubMed Web of Science ®Google Scholar
• Karli DC, Burke DT, Kim HJ, Calvanio R, Fitzpatrick M, Temple D, Macneil M, Pesez K, Lepak P. Effects of dopaminergic combination in traumatic brain injury rehabilitation. Brain Injury 1999; 13: 63–68
   PubMed Web of Science ®Google Scholar
• Dixon CE, Kraus MF, Kline AE, Ma X, Yan HQ, Griffith RG, Wolfson BM, Marion DW. Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restorative Neurological Neuroscience 1999; 14: 285–294
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711
   PubMed Web of Science ®Google Scholar
• Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, Nomikos GG. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Molecular Psychiatry 2005; 11: 187–195
   Web of Science ®Google Scholar
• Ripley DL. Atomoxetine for individuals with traumatic brain injury. Journal of Head Trauma Rehabilitation 2006; 21: 85–88
   PubMed Web of Science ®Google Scholar
• Murdock WM, Hamm RJ. Chronic atomoxetine treatment improves cognition following lateral fluid percussion injury in rats. St. Louis, MO July, 2006, Poster session presented at the annual meeting of the National Neurotrauma Society
   Google Scholar
• Pulaski KH, Emmett L. The combined intervention of therapy and bromocriptine mesylate to improve functional performance after brain injury. American Journal of Occupational Therapy 1994; 48: 263–270
   PubMed Web of Science ®Google Scholar
• Powell JH, al-Adawi S, Morgan J, Greenwood RJ. Motivational deficits after brain injury: Effects of bromocriptine in 11 patients. Journal of Neurology, Neurosurgery & Psychiatry 1996; 60: 416–421
   PubMed Web of Science ®Google Scholar
• Kline AE, Massucci JL, Marion DW, Dixon CE. Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. Journal of Neurotrauma 2002; 19: 415–425
   PubMed Web of Science ®Google Scholar
• Jackson DM, Mohell N, Georgiev J, Bengtsson A, Larsson LG, Magnusson O, Ross SB. Time course of bromocriptine induced excitation in the rat: Behavioural and biochemical studies. Naunyn Schmiedebergs Archives of Pharmacology 1995; 351: 146–155
   PubMed Web of Science ®Google Scholar
• Rosenthal M, Christensen BK, Ross TP. Depression following traumatic brain injury. Archives of Physical & Medical Rehabilitation 1998; 79: 90–103
   PubMed Web of Science ®Google Scholar
• Jayanthi LD, Ramamoorthy S. Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants. AAPS Journal 2005; 7: E728–738
   PubMed Web of Science ®Google Scholar
• Meneses A, Hong E. Effect of fluoxetine on learning and memory involves multiple 5-HT systems. Pharmacology & Biochemical Behaviors 1995; 52: 341–346
   PubMed Web of Science ®Google Scholar
• Fowler SB, Hertzog J, Wagner BK. Pharmacological interventions for agitation in head-injured patients in the acute care setting. Journal of Neuroscience Nursing 1995; 27: 119–123
   PubMedGoogle Scholar
• Maryniak O, Manchanda R, Velani A. Methotrimeprazine in the treatment of agitation in acquired brain injury patients. Brain Injury 2001; 15: 167–174
   PubMed Web of Science ®Google Scholar
• Wilson MS, Gibson CJ, Hamm RJ. Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. American Journal of Physical and Medical Rehabilitation 2003; 82: 871–879
   PubMed Web of Science ®Google Scholar
• Semkova I, Wolz P, Schilling M, Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. European Journal of Pharmacology 1996; 315: 19–30
   PubMed Web of Science ®Google Scholar
• Lamensdorf I, Porat S, Simantov R, Finberg JP. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. British Journal of Pharmacology 1999; 126: 997–1002
   PubMed Web of Science ®Google Scholar
• Yavich L, Sirvio J, Haapalinna A, Puumala T, Koivisto E, Heinonen E, Riekkinen PJ. The systemic administration of Tacrine or selegiline facilitate spatial learning in aged fisher 344 rats. Journal of Neural Transmission 1996; 103: 619–626
   PubMed Web of Science ®Google Scholar
• Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004; 63: S13–22
   PubMed Web of Science ®Google Scholar
• Zhu J, Hamm RJ, Reeves TM, Povlishock JT, Phillips LL. Postinjury administration of L-Deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury. Experimental Neurology 2000; 166: 136–152
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 2000; 155: 1325–1331
   Web of Science ®Google Scholar
• Leonard BE, McCartan D, White J, King DJ. Methylphenidate: A review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology 2004; 19: 151–180
   PubMed Web of Science ®Google Scholar
• Kline AE, Yan HQ, Bao J, Marion DW, Dixon CE. Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. Neuroscience Letters 2000; 280: 163–166
   PubMed Web of Science ®Google Scholar
• Ciallella JR, Yan HQ, Ma X, Wolfson BM, Marion DW, DeKosky ST, Dixon CE. Chronic effects of traumatic brain injury on hippocampal vesicular acetylcholine transporter and M2 muscarinic receptor protein in rats. Experimental Neurology 1998; 152: 11–19
   PubMed Web of Science ®Google Scholar
• Dixon CE, Hamm RJ, Taft WC, Hayes RL. Increased anticholinergic sensitivity following closed skull impact and controlled cortical impact traumatic brain injury in the rat. Journal of Neurotrauma 1994; 11: 275–287
   PubMed Web of Science ®Google Scholar
• Dixon CE, Liu SJ, Jenkins LW, Bhattachargee M, Whitson JS, Yang K, Hayes RL. Time course of increased vulnerability of cholinergic neurotransmission following traumatic brain injury in the rat. Behavior & Brain Research 1995; 70: 125–131
   PubMed Web of Science ®Google Scholar
• Leonard JR, Maris DO, Grady MS. Fluid percussion injury causes loss of forebrain choline acetyltransferase and nerve growth factor receptor immunoreactive cells in the rat. Journal of Neurotrauma 1994; 11: 379–392
   PubMed Web of Science ®Google Scholar
• Schmidt RH, Grady MS. Loss of forebrain cholinergic neurons following fluid-percussion injury: Implications for cognitive impairment in closed head injury. Journal of Neurosurgery 1995; 83: 496–502
   PubMed Web of Science ®Google Scholar
• Hoss W, Messer WS, Monsma FJ, Miller MD, Ellerbrock BR, Scranton T, Ghodsi-Hovsepian S, Price MA, Balan S, Mazloum Z, and others. Biochemical and behavioral evidence for muscarinic autoreceptors in the CNS. Brain Research 1990; 517: 195–201
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM, Quirion R, Collier B. Binding sites for [3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Research 1989; 496: 285–294
   PubMed Web of Science ®Google Scholar
• Richard JW, Wilson A, Quirion R. Muscarinic M2 negative autoreceptors regulate acetylcholine release in cortex and hippocampus: A microdialysis study in freely moving rats. Neuroscience Abstracts 1991; 17: 781
   Google Scholar
• Richards MH. Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: Comparison with hippocampal M1, atrial M2, and ileal M3 receptors. British Journal of Pharmacology 1990; 99: 753–761
   PubMed Web of Science ®Google Scholar
• Pike BR, Hamm RJ. Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats. Brain Research 1995; 686: 37–43
   PubMed Web of Science ®Google Scholar
• Dixon CE, Ma X, Marion DW. Effects of CDP-Choline treatment on neurobehavioral deficits after TBI on hippocampal and neocortical acetylcholine release. Journal of Neurotrauma 1997; 14: 161–169
   PubMed Web of Science ®Google Scholar
• Agut J, Lopez G-Coviella L, Ortiz JA, Wurtman RJ. Oral cytidine 5’-diphosphate choline administration to rats increases phospholipid levels. Annals of the New York Academy of Science 1993; 695: 318–320
   PubMed Web of Science ®Google Scholar
• Pike BR, Hamm RJ. Activating the post-traumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury. Pharmacology, Biochemistry & Behavior 1997; 57: 785–791
   PubMed Web of Science ®Google Scholar
• Pike BR, Hamm R. Chronic administration of a partial muscarinic M1 receptor agonist attenuates decreases in forebrain choline acetyltransferase immunoreactivity following experimental brain trauma. Experimental Neurology 1997; 147: 55–65
   PubMed Web of Science ®Google Scholar
• Pauly JR, Marks MJ, Gross SD, Collins AC. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. Journal of Pharmacology & Experimental Therapy 1991; 258: 1127–1136
   PubMed Web of Science ®Google Scholar
• Rusted JM, Newhouse PA, Levin ED. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behavior & Brain Research 2000; 113: 121–129
   PubMed Web of Science ®Google Scholar
• Verbois SL, Sullivan PG, Scheff SW, Pauly JR. Traumatic brain injury reduces hippocampal alpha 7 nicotinic cholinergic receptor binding. Journal of Neurotrauma 2000; 17: 1001–1011
   PubMed Web of Science ®Google Scholar
• Verbois SL, Hopkins DM, Scheff SW, Pauly JR. Chronic intermittent nicotine administration attenuates traumatic brain injury-induced cognitive dysfunction. Neuroscience 2003; 119: 1199–1208
   PubMed Web of Science ®Google Scholar
• Kurz A. The therapeutic potential of tacrine. Journal of Neural Transmission 1998; 54(Suppl.)295–299
   Google Scholar
• Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: A review. Journal of Head Trauma Rehabilitation 2002; 17: 314–321
   PubMed Web of Science ®Google Scholar
• Soares JC, Gershon S. THA – historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995; 6: 225–234
   PubMedGoogle Scholar
• Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer's type: Clinical, pharmacological, and therapeutic aspects. Drug Development & Research 1988; 12: 163–195
   Web of Science ®Google Scholar
• Voigt JP, Morgenstern E. Pentylenetetrazole kindling impairs learning in mice. Biomedica Biochimica Acta 1990; 49: 143–145
   PubMedGoogle Scholar
• Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Experimental Neurology 1988; 102: 318–324
   PubMed Web of Science ®Google Scholar
• Barkai E, Grossman Y, Gutnick MJ. Long-term changes in neocortical activity after chemical kindling with systemic pentlyenetetrazol: An in vitro study. Journal of Neurophysiology 1994; 72: 72–83
   PubMed Web of Science ®Google Scholar
• Hamm RJ, Pike BR, Temple MD, O’Dell DM, Lyeth BG. The effect of postinjury kindled seizures on cognitive performance of traumatically brain-injured rats. Experimental Neurology 1995; 136: 143–148
   PubMed Web of Science ®Google Scholar
• Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM. MDL 26479: A potential cognition enhancer with benzodiazepine inverse agonist-like properties. British Journal of Pharmacology 1992; 107: 78–86
   PubMed Web of Science ®Google Scholar
• Holley LA, Miller JA, Chmielewski PA, Dudchenko P, Sarter M. Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26479 on learning and markers of cholinergic transmission. Brain Research 1993; 610: 191–193
   Web of Science ®Google Scholar
• Moran PM, Kane JM, Moser PC. Enhancement of working memory performance in the rat by MDL 26479, a novel compound with activity at the GABAA receptor complex. Brain Research 1992; 569: 156–158
   PubMed Web of Science ®Google Scholar
• O’Dell DM, Hamm RJ. Chronic post-injury administration of Suritozole, a negative modulator at the GABA receptor, attenuates cognitive impairment in rats following traumatic brain injury. Journal of Neurosurgery 1995; 83: 878–883
   PubMed Web of Science ®Google Scholar
• Biegon A, Fry PA, Paden CM, Alexandrovich A, Tsenter J, Shohami F. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proceedings of the National Academy of Science of the USA 2004; 101: 5117–5122
   PubMed Web of Science ®Google Scholar
• Baxter MG, Lanthorn TH, Frick KM, Golski S, Wan RQ, Olton DS. D-cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiology & Aging 1994; 15: 207–213
   PubMed Web of Science ®Google Scholar
• Schuster GM, Schmidt WJ. D-Cycloserine reverses the working J memory impairment of hippocampal-lesioned rats in a spatial learning task. European Journal of Pharmacology 1992; 224: 97–98
   PubMed Web of Science ®Google Scholar
• Temple MD, Hamm RJ. Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Research 1996; 741: 246–251
   PubMed Web of Science ®Google Scholar
• Baranova AI, Whiting MD, Hamm RJ. Delayed, post-injury treatment with aniracetam improves cognitive performance after traumatic brain injury in rats. Journal of Neurotrauma 2006; 23: 1233–1240
   PubMed Web of Science ®Google Scholar
• Fushiki S, Matsumoto K, Nagata A. Neurite outgrowth of murine cerebellar granule cells can be enhanced by aniracetam with or without alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA). Neuroscience Letters 1995; 199: 171–174
   PubMed Web of Science ®Google Scholar
• Gribkoff VK, Bauman LA, VanderMaelen CP. A 1-heteroaryl-4-piperidinyl-methyl pyrrolidinone, BMY 21502, delays the decay of hippocampal synaptic potentiation in vitro 1990; 29: 1001–1009, Neuropharmacology
   Google Scholar
• Pierce JE, Smith DH, Eison MS, McIntosh TK. The nootropic compound BMY-21502 improves spatial learning ability in brain injured rats. Brain Research 1993; 624: 199–208
   PubMed Web of Science ®Google Scholar
• Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat neurodegenerative diseases?. Critical Reviews in Neurobiology 2004; 16: 83–90
   PubMedGoogle Scholar
• Whiting MD, Hamm RJ. Chronic, postinjury lithium treatment improves cognitive recovery following lateral fluid percussion brain injury in rats. Washington, DC November 2005, Poster session presented at the annual meeting of the National Neurotrauma Society
   Google Scholar
• Funk KF, Schmidt J. Changes of dopamine metabolism by hypoxia and effects of nootropic drugs. Biomedica Biochemica Acta 1984; 11: 1301–1304
   Google Scholar
• Spignoli G, Pepeu G. Interaction between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacology & Biochemistry in Behavior 1987; 27: 491–495
   PubMed Web of Science ®Google Scholar
• Marchi M, Besana E, Raiteri M. Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices. European Journal of Pharmacology 1990; 185: 247–249
   PubMed Web of Science ®Google Scholar
• DeFord SM, Wilson MS, Gibson CJ, Baranova A, Hamm RJ. Nefiracetam improves Morris water maze performance following traumatic brain injury in rats. Pharmacology & Biochemistry in Behavior 2001; 69: 611–616
   PubMed Web of Science ®Google Scholar
• Stanislav SW. Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Injury 1997; 11: 335–341
   PubMed Web of Science ®Google Scholar
• Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: A review of the literature. Alternative Medicine Review 2004; 9: 17–31
   PubMedGoogle Scholar
• Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, Coslett HB. Effects of methylphenidate on attention deficits after traumatic brain injury: A multidimensional, randomized, controlled trial. American Journal of Physical and Medical Rehabilitation 2004; 83: 401–420
   PubMed Web of Science ®Google Scholar
• Kim YH, Ko MH, Na SY, Park SH, Kim KW. Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: A double-blind placebo-controlled study. Clinical Rehabilitation 2006; 20: 24–30
   PubMed Web of Science ®Google Scholar
• Beers SR, Skold A, Dixon CE, Adelson PD. Neurobehavioral effects of amantadine after pediatric traumatic brain injury: A preliminary report. Journal of Head Trauma Rehabilitation 2005; 20: 450–463
   PubMed Web of Science ®Google Scholar
• Kraus ME, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: A study using positron emission tomography (PET). Brain Injury 2005; 19: 471–479
   PubMed Web of Science ®Google Scholar
• Leone H, Polsonetti BW. Amantadine for traumatic brain injury: Does it improve cognition and reduce agitation?. Journal of Clinical & Pharmacological Therapy 2005; 30: 101–104
   PubMed Web of Science ®Google Scholar
• Horsfield SA, Rosse RB, Tomasino V, Schwartz BL, Mastropaolo J, Deutsch SI. Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. International Journal of Psychiatry in Medicine 2002; 32: 337–344
   PubMed Web of Science ®Google Scholar
• Deb S, Lyons I, Koutzoukis C, Ali I, McCarthy G. Rate of psychiatric illness 1 year after traumatic brain injury. American Journal of Psychiatry 1999; 156: 374–378
   PubMed Web of Science ®Google Scholar
• Koponen S, Taiminen T, Portin R, et al. Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. American Journal of Psychiatry 2002; 159: 1315–1321
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke. Traumatic brain injury: Hope through research. National Institutes of Health, Bethesda, MD February 2002, NIH Publication No.: 02–158
   Google Scholar